a16z Capital Management, L.L.C.

Institutional investor · Portfolio as of Q2 2026

Q2 2026 biggest moves

Reported value$1.3B → $14.2B

  • SPCXSPCX

    SpaceX

    New listing

    90% of portfolio

  • FIGFIG

    Figma

    Cut 63%

    now 0.8% of portfolio

  • NAUTNAUT

    Nautilus Biotechnology

    Cut 49%

    now 0.1% of portfolio

  • RBLXRBLX

    Roblox

    New

    0.1% of portfolio

8 changes in all

Top Holdings19 positions

Checking export access…
Activity:
SPCX

Space Exploration Technologies Corp.

74.9M$12.8B90.0%$170.860.00%
1 qtr
New
Unranked
NAVN

Navan, Inc.

28.2M$645.4M4.5%$16.94+35.00%
3 qtrssince 2025-Q4
Unchanged
0
RVMD

Revolution Medicines, Inc.

921,099$172.5M1.2%$28.68+553.00%
11 qtrssince 2023-Q4
Unchanged
0
META

Meta Platforms, Inc.

212,531$119.7M0.8%$731.90-23.10%
4 qtrssince 2025-Q3
Unchanged
0
FIG

Figma, Inc.

6M$108.2M0.8%$51.87-65.12%
4 qtrssince 2025-Q3
Decreased
0
BIOA

BioAge Labs, Inc.

3.2M$79.2M0.6%$19.78+23.90%
8 qtrssince 2024-Q3
Unchanged
0
XYZ

Block, Inc.

1M$77.3M0.5%——
11 qtrssince 2023-Q4
Unchanged
0
ERAS

Erasca, Inc.

2.9M$52.4M0.4%$2.13+760.09%
11 qtrssince 2023-Q4
Unchanged
0
MAZE

Maze Therapeutics, Inc.

1.7M$50.8M0.4%$11.01+171.03%
6 qtrssince 2025-Q1
Unchanged
0
GLTO

DAMORA THERAPEUTICS INC

1.2M$32.2M0.2%$25.90+0.42%
2 qtrssince 2026-Q1
Unchanged
0
OMDA

Omada Health, Inc.

1.2M$25.3M0.2%$18.30+13.72%
5 qtrssince 2025-Q2
Decreased
0
NAUT

Nautilus Biotechnology, Inc.

9.1M$16.9M0.1%$2.99-37.46%
11 qtrssince 2023-Q4
Decreased
0
RBLX

Roblox Corporation

274,570$14.9M0.1%$54.380.00%
1 qtr
New
50
AKTS

Aktis Oncology, Inc.

415,000$13.4M0.1%$17.89+80.16%
2 qtrssince 2026-Q1
Unchanged
0
CAMP

CAMP4 Therapeutics Corporation

2.1M$9.3M0.1%$5.22-16.28%
7 qtrssince 2024-Q4
Unchanged
0
BTGO

BitGo Holdings, Inc.

666,356$3.5M0.0%$8.23-37.06%
2 qtrssince 2026-Q1
Unchanged
0
KLRA

Kailera Therapeutics, Inc.

140,000$3.1M0.0%$22.030.00%
1 qtr
New
40
DNA

Ginkgo Bioworks Holdings, Inc.

108,568$1.1M0.0%$8.15+21.60%
8 qtrssince 2024-Q3
Unchanged
0
IPST

IP Strategy Holdings, Inc.

4,137$9,7220.0%$2.350.00%
1 qtr
New
26
$14.2B
AUM
19
Positions
Q2 2026
Filing
HI rating · 2.5/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q1$700,872,513-5.95542391906%
2025-Q2$312,909,254-55.3543264722%
2025-Q3$1,394,890,890345.781283925%
2025-Q4$1,579,784,57813.2550645592%
2026-Q1$1,290,612,468-18.3045279734%
2026-Q2$14,214,935,8341001.41008137%
Activity profile
$ moved · Q2'26
New98%Increased0%Decreased2%Exited<1%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.4 years
<1Q21%1-4Q16%1-2Y16%2Y+47%

a16z Capital Management, L.L.C. manages $14.2B across 19 positions as of Q2 2026. Top holdings: SPCX (90.0%), NAVN (4.5%), RVMD (1.2%). Fund DNA: High Conviction Activist. HoldingsIntel Score: 2.5/5.0.

Top holdings by portfolio weight

Total AUM$14B
SPCX89.97%
NAVN4.54%
RVMD1.21%
META0.84%
FIG0.76%
BIOA0.56%
XYZ0.54%
ERAS0.37%
MAZE0.36%
GLTO0.23%
Other0.18%

Portfolio allocation by GICS sector

Sectors3
Technology59.12%
Healthcare31.29%
Communication Services9.58%

Behavioral investing profile

Checking access…
High Conviction Activist
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L38
Conviction63
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used